Dr. Alexander Asam

Dr. Alexander Asam, MBA, currently serves as a Partner at HBM Partners AG since 2007 and holds observer roles on the Board of Directors at Aculys Pharma and Swixx BioPharma. With extensive experience in biotechnology, Dr. Asam has held board positions at various companies across Europe, the US, and Canada since 1999, including significant roles at Mineralys Therapeutics, Inc. and APR Applied Pharma Research. Notable past board engagements include membership at Arcutis Biotherapeutics and Corvidia Therapeutics, the latter being acquired by Novo Nordisk for up to USD 2.1 billion. Dr. Asam earned an MBA in Finance & Strategy from Aston Business School and a PhD in Chemistry from Ruprecht-Karls-Universität Heidelberg.